Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Matteo De Pastena

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5244-4357; OpenAlex author ID A5056653055. Sources: OpenAlex.

Their work

Papers
31 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
148
Papers, trials and grants by year

2018: 6 papers · 2019: 2 papers · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers · 2026: 6 papers

Papers 31

  1. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  2. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  3. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  4. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  5. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management. Co-author DOI 10.3390/cancers18152481↗
  6. Correction: Danese et al. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management. Cancers 2026, 18, 2481. Co-author DOI 10.3390/cancers18193144↗
  7. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  8. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006197↗
  9. Surgical and Oncological Outcomes of Minimally Invasive Left Pancreatectomy for Pancreatic Cancer: Robotic vs. Laparoscopic Approach. Co-author DOI 10.3390/curroncol32070376↗
  10. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  11. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  12. Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. Co-author DOI 10.1245/s10434-024-14951-4↗
  13. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  14. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  15. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  16. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Co-author DOI 10.1245/s10434-022-12385-4↗
  17. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  18. Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Pr… Co-author DOI 10.1097/sla.0000000000003717↗
  19. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy i… Co-author DOI 10.1186/s12885-021-07877-7↗
  20. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  21. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32586↗
  22. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  23. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Co-author DOI 10.1245/s10434-019-08137-6↗
  24. Minimally invasive surgery for pancreatic cancer. Co-author DOI 10.1080/14737140.2019.1685878↗
  25. Ablation treatments in unresectable pancreatic cancer. First author DOI 10.23736/s0026-4733.18.07881-1↗
  26. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗
  27. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Co-author DOI 10.1007/s00423-017-1627-0↗
  28. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Co-author DOI 10.1016/j.pan.2018.04.002↗
  29. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  30. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  31. Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. First author DOI 10.21037/tgh.2018.10.05↗

Closest collaborators

The 25 strongest of 148 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Salvia · 21 shared papers, 2018–2026 · strength 3.03
  2. Giuseppe Malleo · 15 shared papers, 2018–2026 · strength 2.10
  3. Alessandro Esposito · 11 shared papers, 2018–2026 · strength 1.97
  4. Salvatore Paiella · 13 shared papers, 2018–2026 · strength 1.91
  5. Gabriella Lionetto · 8 shared papers, 2021–2026 · strength 1.85
  6. Claudio Bassi · 16 shared papers, 2018–2024 · strength 1.57
  7. Erica Secchettin · 8 shared papers, 2018–2026 · strength 1.01
  8. Fabio Casciani · 4 shared papers, 2024–2026 · strength 0.95
  9. Antonio Pea · 4 shared papers, 2019–2026 · strength 0.82
  10. Alessandro Zerbi · 6 shared papers, 2020–2026 · strength 0.79
  11. Giovanni Marchegiani · 7 shared papers, 2018–2026 · strength 0.68
  12. Marc G. Besselink · 8 shared papers, 2018–2024 · strength 0.65
  13. Giuseppe Lippi · 2 shared papers, 2026 · strength 0.60
  14. Elisa Danese · 2 shared papers, 2026 · strength 0.60
  15. Massimo Falconi · 4 shared papers, 2020–2026 · strength 0.53
  16. Riccardo Casadei · 4 shared papers, 2020–2024 · strength 0.49
  17. Mohammad Abu Hilal · 5 shared papers, 2018–2024 · strength 0.47
  18. Giovanni Butturini · 4 shared papers, 2020–2024 · strength 0.47
  19. Ugo Boggi · 5 shared papers, 2018–2024 · strength 0.44
  20. Jony van Hilst · 5 shared papers, 2018–2024 · strength 0.44
  21. Mirko D’Onofrio · 5 shared papers, 2018–2021 · strength 0.40
  22. Laura Maggino · 4 shared papers, 2018–2023 · strength 0.39
  23. Aldo Scarpa · 3 shared papers, 2018–2026 · strength 0.37
  24. Michèle Milella · 3 shared papers, 2021–2023 · strength 0.37
  25. Jonathan Garnier · 2 shared papers, 2021–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.